Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPRGet Rating) have been given a consensus recommendation of “Hold” by the nine research firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $12.63.

A number of equities research analysts have weighed in on ESPR shares. Credit Suisse Group lowered Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $7.00 to $6.00 in a report on Wednesday, August 3rd. Cowen decreased their price target on Esperion Therapeutics to $13.00 in a research note on Tuesday, August 9th. Finally, Morgan Stanley boosted their price target on Esperion Therapeutics from $5.00 to $7.00 and gave the stock an “underweight” rating in a research note on Friday, July 15th.

Insider Transactions at Esperion Therapeutics

In related news, CEO Sheldon L. Koenig purchased 8,606 shares of the stock in a transaction that occurred on Friday, August 5th. The stock was purchased at an average cost of $5.80 per share, for a total transaction of $49,914.80. Following the acquisition, the chief executive officer now owns 198,771 shares in the company, valued at $1,152,871.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Sheldon L. Koenig acquired 8,606 shares of the firm’s stock in a transaction on Friday, August 5th. The stock was bought at an average cost of $5.80 per share, with a total value of $49,914.80. Following the transaction, the chief executive officer now directly owns 198,771 shares in the company, valued at approximately $1,152,871.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joanne M. Foody sold 3,901 shares of the company’s stock in a transaction dated Tuesday, July 19th. The shares were sold at an average price of $6.55, for a total transaction of $25,551.55. Following the completion of the transaction, the insider now directly owns 109,077 shares of the company’s stock, valued at $714,454.35. The disclosure for this sale can be found here. Insiders sold a total of 7,749 shares of company stock worth $52,228 in the last ninety days. Insiders own 3.30% of the company’s stock.

Hedge Funds Weigh In On Esperion Therapeutics

Several large investors have recently modified their holdings of ESPR. Wasatch Advisors Inc. raised its stake in Esperion Therapeutics by 27.6% during the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company’s stock worth $37,804,000 after acquiring an additional 1,761,117 shares during the period. Deep Track Capital LP increased its stake in shares of Esperion Therapeutics by 6.4% in the first quarter. Deep Track Capital LP now owns 6,000,000 shares of the biopharmaceutical company’s stock valued at $27,840,000 after purchasing an additional 358,332 shares during the period. Deerfield Management Company L.P. Series C acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $25,000,000. Vanguard Group Inc. increased its stake in shares of Esperion Therapeutics by 19.4% in the first quarter. Vanguard Group Inc. now owns 4,491,530 shares of the biopharmaceutical company’s stock valued at $20,841,000 after purchasing an additional 730,091 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Esperion Therapeutics by 116.8% in the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company’s stock valued at $17,212,000 after purchasing an additional 1,457,952 shares during the period. Institutional investors own 94.63% of the company’s stock.

Esperion Therapeutics Stock Down 2.1 %

Shares of ESPR stock opened at $6.96 on Friday. The stock has a market capitalization of $463.20 million, a PE ratio of -1.09 and a beta of 0.17. Esperion Therapeutics has a 52-week low of $3.28 and a 52-week high of $13.14. The stock’s 50-day moving average price is $6.93 and its 200 day moving average price is $6.07.

Esperion Therapeutics (NASDAQ:ESPRGet Rating) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.10). The business had revenue of $18.80 million during the quarter, compared to the consensus estimate of $18.62 million. During the same quarter in the previous year, the company earned ($1.67) earnings per share. The company’s quarterly revenue was down 53.8% compared to the same quarter last year. Analysts expect that Esperion Therapeutics will post -3.81 earnings per share for the current fiscal year.

Esperion Therapeutics Company Profile

(Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Further Reading

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.